CTS Corporation Posts 11% Q1 Sales Growth and 250bp Margin Expansion
CTS Corporation generated $139.2 million in Q1 revenue with net income of $17.2 million, driving an 11% sales increase and a 250-basis-point gross margin expansion. The company reported a 1.1 book-to-bill ratio led by industrial and medical markets and narrowed 2026 sales guidance to $560–$580 million.
1. Q1 Financial Performance
CTS Corporation posted Q1 revenue of $139.2 million and net income of $17.2 million, representing an 11% increase in sales. Gross margin expanded by 250 basis points due to a favorable shift toward higher-margin medical and industrial products and operational efficiencies.
2. Segment Momentum
The company achieved a 1.1 book-to-bill ratio driven by strong demand in industrial and medical markets, including expanded capacity in non-invasive aesthetics. Transportation revenue grew 3% as powertrain-agnostic solutions mitigated softness in the light vehicle segment.
3. Guidance and Outlook
Full-year 2026 sales guidance was narrowed to $560–$580 million, backed by sustained demand in diversified markets. Aerospace and defense revenues are expected to accelerate in the second half of the year, while commercial vehicle demand may improve ahead of 2027 emissions regulations, offsetting forecasted light vehicle headwinds.